GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Willow Biosciences Inc (OTCPK:CANSF) » Definitions » 3-Year Dividend Growth Rate

Willow Biosciences (Willow Biosciences) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Willow Biosciences 3-Year Dividend Growth Rate?

Willow Biosciences's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The historical rank and industry rank for Willow Biosciences's 3-Year Dividend Growth Rate or its related term are showing as below:

CANSF's 3-Year Dividend Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.25
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Willow Biosciences's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, Willow Biosciences's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Willow Biosciences's 3-Year Dividend Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Willow Biosciences's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Willow Biosciences's 3-Year Dividend Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Willow Biosciences's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Willow Biosciences's 3-Year Dividend Growth Rate falls into.



Willow Biosciences 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Willow Biosciences  (OTCPK:CANSF) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Willow Biosciences's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2023 )/ EPS without NRI (Q: Dec. 2023 )
=0/ -0.009
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Willow Biosciences 3-Year Dividend Growth Rate Related Terms>


Willow Biosciences (Willow Biosciences) Business Description

Traded in Other Exchanges
Address
202, 1201 5th Street SW, Calgary, AB, CAN, T2R 0Y6
Willow Biosciences Inc is a Canadian biotechnology company. It has only one reportable segment engaged in developing and producing high-purity, plant-derived ingredients for consumer care, food and beverage, and pharmaceutical products. Geographically, it derives a majority of its revenue from Canada.

Willow Biosciences (Willow Biosciences) Headlines

From GuruFocus

WILLOW BIOSCIENCES PROVIDES CBG UPDATE

By PRNewswire PRNewswire 08-31-2022